A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)
Status:
Terminated
Trial end date:
2020-02-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of TAK-164 and to determine the maximum
tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and schedule.